Ortin Laboratories Limited

ORTINLAB

INE749B01020

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:52 2024-06-26 EDT			5-day change	1st Jan Change
20.67 ^INR	-1.57%		+0.93%	-10.21%

05-30	Ortin Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI
05-30	Ortin Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI

Ortin Laboratories Limited Announces Resignation of Mathpati Tippayya, Lndependent Director

August 02, 2018 at 09:14 am

Ortin Laboratories Limited announced the resignation of Mathpati Tippayya, independent Director with effect from July 30, 2018 due to his pre-occupations.

Latest news about Ortin Laboratories Limited

Ortin Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	05-30	CI
Ortin Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-30	CI
Ortin Laboratories Limited Announces Board Appointments	02-16	CI
Ortin Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-13	CI
Ortin Laboratories Limited Appoints Divya Purswani as Company Secretary and Compliance Officer	02-09	CI
Ortin Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-14	CI
Ortin Laboratories Limited Announces Executive Changes	11-10	CI
Ortin Laboratories Limited Appointment of Harish Sharma as Company Secretary	23-10-10	CI
Ortin Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-14	CI
Drugs Control Authority Cancels Ortin Laboratories' Manufacturing License	23-07-11	MT
Drugs Control Administration, Government of Telangana Cancels Manufacturing License of Ortin Laboratories Limited	23-07-11	CI
Ortin Laboratories Limited Announces Resignation of Nitesh Kumar Sharma as Company Secretary/Compliance Officer	23-06-13	CI
Ortin Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-30	CI
Ortin Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14	CI
Ortin Laboratories Limited Announces Resignation of J R K Panduranga Rao as Independent Director	22-11-29	CI
Ortin Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-14	CI
Ortin Laboratories Limited Announces Cessation of Bh. Satyanarayana Raju and G. Venkata Ramana, Directors	22-10-19	CI
Ortin Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-13	CI
Ortin Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2022	22-05-30	CI
Ortin Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-14	CI
Ortin Laboratories Limited Announces Demise of Mohan Krishna Murthy, Whole-Time Director	21-11-29	CI
Ortin Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-13	CI
Ortin Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	21-07-09	CI
Ortin Laboratories Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	21-02-13	CI
Ortin Laboratories Limited Appoints Mr. S. Srinivas Kumar as CFO	21-01-01	CI

Chart Ortin Laboratories Limited

Duration

Period

More charts

Ortin Laboratories Limited is engaged in manufacturing and trading of pharmaceuticals, drugs, and intermediates. It manufactures a range of pharmaceutical formulations of tablets, capsules, syrups, and dry powders. The Company's products include Acefinac, ACEFINAC-CZ, ACEFINAC-P, ACEFINAC-SP, ACTAZID, ACTY-P, ALERFEX-120, ALERFEX-180, ALERGID, ALERGID- L, AMLOBID, CARBAMOL, CARISNIL, CALDY-C AZITIN-500, DOCEF-200, GLYCITROL, GLYCITROL-M, LORACT, MEBOL, NEUROCOB, FERUP, IRFER Z, MINVITA-B, NILCID, ORICILLIN-DX, PEG POWDER, PEG-D POWDER, ALKASIT, COF-XL, DECODIL, ENCENIL and OROMOX DRY SYRUP. Its formulations include Anti Diabetics, Anti Allergics, Anti Anginal and Cardiovascular, Analgesics and Antipyretics, and Anti Biotics-Quinolones. Its active pharmaceutical ingredient (API) intermediates include Anti retro viral, Grignard, Diborane, Ciprofloxacin and Tramadol. It is also manufacturing for different importers to market their products in Russia, Ukraine, Kajakistan and South America.

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ORTIN LABORATORIES LIMITED	-10.21%	2.05M
ELI LILLY AND COMPANY	+55.19%	815B
NOVO NORDISK A/S	+45.77%	654B
JOHNSON & JOHNSON	-6.09%	354B
MERCK & CO., INC.	+21.92%	337B
ABBVIE INC.	+10.18%	302B
ASTRAZENECA PLC	+18.38%	247B
ROCHE HOLDING AG	+2.66%	229B
NOVARTIS AG	+13.34%	219B
AMGEN INC.	+10.86%	171B